Latest news with #ChineseAcademyofMedicalSciences
Yahoo
13-06-2025
- Health
- Yahoo
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled "BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy" in the New England Journal of Medicine (NEJM), which has reported for the first time globally the research data on a BCMA x CD3 bispecific antibody treatment for patients with refractory autoimmune hemolytic anemia (AIHA). The study results showed that two patients experienced rapid disease improvement after the administration of CM336, achieving partial remission on days 13 and 19, respectively. Hemoglobin levels returned to normal on days 17 and 21, respectively, while reticulocyte counts, lactate dehydrogenase, and indirect bilirubin levels significantly decreased. Before receiving treatment with CM336, both patients had undergone multiple treatment regimens, including glucocorticoids, splenectomy, anti-CD20 antibodies, BTK inhibitors, and CD19 CAR-T cell therapies, but their disease eventually recurred or progressed to refractory status. The latest assessment results after 6 months post-starting CM336 showed that both patients remained in sustained remission without immunosuppressive therapies or transfusions. No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or infection events occurred during the entire treatment and follow-up period. The overall study showed that CM336 had demonstrated positive efficacy signals in treating patients with relapsed/refractory AIHA who had previously received multiple therapies, with rapid disease control and sustained remission lasting over half a year, while also exhibiting good safety profile, potentially making it an innovative treatment option for development in this disease. About CM336CM336 is a BCMA x CD3 bispecific antibody that can simultaneously target and identify and specifically bind both BCMA on the surface of target cells and the CD3 receptors on the surface of T cells to recruit immune T cells to the vicinity of the target cells, thereby inducing T-cell dependent cellular cytotoxicity (TDCC) to eliminate the target cells. As of the date of this announcement, the Phase II clinical study of CM336 for the treatment of primary light-chain amyloidosis has been approved by the Center for Drug Evaluation of the National Medical Products Administration and will commence clinical trials shortly. About Keymed BiosciencesKeymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. View original content: SOURCE Keymed Biosciences
South China Morning Post
11-05-2025
- Health
- South China Morning Post
Drug trial offers hope for patients with hard-to-treat lung cancer in China, US
A new medication has shown promise as a safe and effective therapy for a hard-to-treat type of lung cancer , according to an international clinical trial led by Chinese and US scientists. Advertisement The findings were published in the New England Journal of Medicine (NEJM) on April 28 and presented at the American Association for Cancer Research Annual Meeting in Chicago on the same day. The researchers found that the oral medication zongertinib outperformed the standard treatment option when treating HER2-mutated non-small cell lung cancer (NSCLC). It works by targeting the HER2 protein and blocking the activity of the protein's tyrosine kinase, which is responsible for signalling cell growth. This type of lung cancer is particularly difficult to treat. Unlike other NSCLC variants, it only has one treatment option that has been approved by the US Food and Drug Administration: intravenous antibody-drug conjugate (ADC) therapy. And ADC-class medications carry risks of adverse effects, including diarrhoea, nausea, fatigue and skin rashes. Wang Xin, professor at the Chinese Academy of Medical Sciences Cancer Hospital, said in an April 29 review of the NEJM study that zongertinib had the 'potential to establish a new benchmark for targeted therapy in HER2-mutant NSCLC'. 10:51 New oral treatment for blood cancer offers 97% cure rate, Hong Kong researchers say New oral treatment for blood cancer offers 97% cure rate, Hong Kong researchers say The multi-cohort study was conducted at 82 sites around the world, including 18 US institutions, 17 in China and three in Japan. The analysis published by the NEJM included 188 NSCLC patients, with Asian populations accounting for a majority.
